Celcuity Inc (CELC) PT Raised to $115 at Stifel

Stifel analyst Stephen Willey raised the price target on Celcuity Inc (NASDAQ: CELC) to $115.00 (from $68.00) while maintaining a Buy rating.

The analyst comments "Following the 3Q25 call and our fireside chat with CELC CEO Brian Sullivan at The 2025 Stifel Healthcare Conference (held in NYC, November 11-13), we are updating our model to reflect management’s 3Q25 in-line earnings announcement. Herein we provide a recap of our fireside chat during which management publicly indicated interest in expanding eligibility of the VIKTORIA-2 endocrine-resistant 1L trial to a broader 1L population based on the strength of VIKTORIA-1 data (in 2L PIK3CAwt) alongside commentary on ExUS launch strategy and gedatolisib's competitive positioning in 2L HR+ MBC. We are increasing our target price to $115 based on updated VIKTORIA-1 (2L) U.S. sales and PoS estimates and remain Buy-rated."

You May Also Be Interested In

• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)